Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Ben George MD
Associate Professor
Department of Medicine
Division of Hematology and Oncology - Medicine
Associate Professor of Medicine
William F. Stapp Endowed Chair
Medical Director, Clinical Trials Office



OFFICE ADDRESS:
Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226
Phone: 414-805-4600

EDUCATION:
09/1992 - 08/1998 Medical College Thiruvananthapuram, Kerala, India
09/1998 - 05/1999 Research Assistant (Epidemiology), Regional Cancer Center , Thiruvananthapuram, Kerala, India, India
09/1999 - 06/2004 Doctoral Candidate, USC/Keck School of Medicine, Los Angeles, CA

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
09/1998 - 05/1999 Research Assistant (Epidemiology), Regional Cancer Center, Thiruvananthapuram, Kerala, India
07/2004 - 06/2005 Internship (Internal Medicine), Medical College of Ohio, Toledo, OH
07/2005 - 06/2007 Residency (Internal Medicine), Gundersen Lutheran Medical Center, La Crosse, WI
07/2007 - 06/2010 Fellowship (Hematology/Oncology), Medical College of Wisconsin, Milwaukee, WI
07/2010 - 12/2010 Visiting Fellowship (GI Medical Oncology), The University of Texas MD Anderson Cancer Center, Houston, TX

FACULTY APPOINTMENTS:
01/2011 - 07/2016 Assistant Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital, WI
07/2016 - Present Associate Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital

ADMINISTRATIVE APPOINTMENTS:
2013 - Present Institutional Co-Principal Investigator, Alliance Cooperative Group
2014 - 2017 Member of the MCW/Froedtert IRB
2015 - Present Member of the Department of Medicine a??Task Force for Genetics in Adult Practicea?? committee (Division of Hematology and Oncology representative)
2015 - Present Co-Chair, MCW Molecular Oncology Steering Committee
2015 - Present Solid Tumor Oncology Discharge Mapping Committee
2016 - Present Direct the monthly Interdisciplinary Molecular Oncology Tumor Board
07/2017 - Present Director, Cancer Precision Medicine Practice Integration, Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin
07/2017 - Present Director, Phase 1 Clinical Trials Program, Froedtert Hospital and Medical College of Wisconsin, Clinical Cancer Center
07/2017 - Present Vice-Chair, Research Committee, Precision Medicine Exchange Consortium
12/2017 - Present Pharma Task Force, Precision Medicine Exchange Consortium
06/2018 - Present Co-Chair, Cancer Precision Medicine Steering Committee, MCW
08/2019 - 02/2020 Associate Director of Cancer Genomics and Precision Medicine, Genomic Sciences and Precision Medicine Center, MCW
02/2020 - Present Medical Director, Clinical Trials office

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
07/03/2013 - Present Institutional Co-Principal Investigator, Alliance Cooperative Group, Medicine, Hematology and Oncology, Froedtert and Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Milwaukee, WI 53226

HOSPITAL STAFF PRIVILEGES:
2011 - Present St. Josepha??s Hospital, West Bend, WI
2011 - Present Froedtert Memorial Lutheran Hospital, 9200 W Wisconsin Ave, Milwaukee, WI 53226
2011 - Present Community Memorial Hospital, Menomonee Falls, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
INTERNAL MEDICINE
2007
None
MEDICAL ONCOLOGY
2010
None
HEMATOLOGY
2010
None
   
Licensure
Number Issue DateExpiration
WISCONSIN MEDICAL LICENSE
50139-20
10/31/2023
    

AWARDS AND HONORS:
2008 - 2009 THE BEST TEACHING FELLOW IN THE DEPARTMENT OF INTERNAL MEDICINE AT MEDICAL COLLEGE OF WISCONSIN
2009 - 2010 DONALD J. SHUENKE ENDOWED CANCER FELLOWSHIP
2015 - Present selected to "Best Doctors in America"
2015 - Present Featured in the a??Milwaukee Business Journala?? among a??Best Doctorsa?? in Milwaukee
2015 - Present Featured in the a??Ma?? magazine among a??Best Doctorsa?? in Milwaukee
2017 - 2018 Annual Department of Medicine 'Murphy Award' for Excellence in Clinical Medicine, MCW
07/2019 - Present William Stapp Endowed Chair in Medicine
08/2019 - Present Froedtert and Medical College of Wisconsin Cancer Center Collaborative Award for Excellence in Clinical Research

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
American Society of Clinical Oncology
American Association of Cancer Research
American College of Physicians

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorial Board
07/18/2013 - Present BioMed Research International
Journal Review
Clinical Cancer Research
Annals of Surgical Oncology
JNCCN
Frontiers Oncology
Journal of Cancer Research and Clinical Oncology

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Molecular Analysis for Therapy Choice (MATCH)
Source:
NCTN LAPS
Role:
PI
Dates:
11/11/2016 - Present
  
Title:
Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Tumors including Poorly Differentiated Neuroendocrine Carcinomas and Well-Differentiated Neuroendocrine Neoplasms
Source:
NCTN LAPS
Role:
PI
Dates:
11/14/2016 - Present
  
Non-Peer Review
Title:
An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
Source:
GENENTECH-MYPATHWAY
Role:
PI
PI:
Ben George
Dates:
06/28/2017 - Present
Direct Funds:
$328,742
  
Title:
"An Open-label Phase I Dose Finding Trial with BI 891065 Alone and in Combination with BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients with Advanced and/or Metastatic Malignancies"
Source:
BI-1379-0001-REFMAL505
Role:
PI
Dates:
02/12/2018 - 03/16/2020
Direct Funds:
$461,980
  
Title:
"A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors"
Source:
TOLERO-TP-1287-101
Role:
PI
PI:
Ben George
Dates:
12/07/2018 - Present
Direct Funds:
$349,869
  
Title:
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Source:
HOFFMANN-WO39608-MORPHEUS
Role:
PI
PI:
Ben George
Dates:
12/28/2018 - Present
Direct Funds:
$281,474
  
Title:
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination with BI 754091 in Patients with Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients with Non-small Cell Lung Cancer and Other Solid Tumors
Source:
BI-1381-REFMAL485
Role:
PI
Dates:
02/15/2019 - 03/16/2020
Direct Funds:
$528,690
  
Title:
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
Source:
TORAY-950P1V02
Role:
PI
PI:
Ben George
Dates:
05/19/2019 - Present
Direct Funds:
$141,391
  
Title:
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-Pd-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Source:
GENENTECH-WO41535-IMBRAVE050
Role:
PI
Dates:
10/30/2019 - Present
Direct Funds:
$20,000
  
Title:
An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
Source:
REPLIMUNE-RPL-001-16
Role:
PI
Dates:
11/07/2019 - Present
Direct Funds:
$24,300
  
Title:
A Phase II Clinical Trial of GVAX Pancreas Vaccine (with Cyclophosphamide) in Combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients with Borderline Resectable Pancreatic Adenocarcinoma
Source:
JH-J1756-IRB00130075-GVAX
Role:
PI
Dates:
01/15/2020 - Present
Direct Funds:
$50,500
  
Title:
A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Source:
NGM-18-0402
Role:
PI
Dates:
02/20/2020 - Present
Direct Funds:
$42,447
  
Title:
Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors
Source:
TIZONA-TTX-030-002
Role:
PI
Dates:
03/03/2020 - Present
Direct Funds:
$216,946
  
Title:
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
Source:
MIRATI-849-002
Role:
PI
Dates:
03/16/2020 - Present
Direct Funds:
$548,508
  
Title:
A Phase I Study of GNX102 in Patients with Advanced Solid Tumors
Source:
GLYCONEX-GNX-001
Role:
PI
Dates:
04/30/2020 - Present
Direct Funds:
$321,529
  
Title:
A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 plus Doxorubicin for the Treatment of Patients with Previously Treated Advanced Pancreatic Cancer
Source:
HELIX-LDOS006
Role:
PI
Dates:
04/05/2021 - Present
Direct Funds:
$121,020
  
Title:
Tumor-Agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (Tapistry) Phase II Platform Trial
Source:
HOFFMANN-BO41932-TAPISTRY
Role:
PI
Dates:
08/26/2021 - Present
Direct Funds:
$43,850
  
Title:
HOFFMANN-LAROCHE-YO39609
Source:
HOFFMANN-LAROCHE-YO39609
Role:
PI
Dates:
11/29/2021 - Present
Direct Funds:
$36,976
  
Title:
A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma
Source:
TAIHO-TAS-120-301
Dates:
01/13/2022 - Present
Direct Funds:
$28,900
  
Title:
MIRATI-849-010-KRYSTAL-10
Role:
PI
Dates:
03/03/2022 - Present
Direct Funds:
$33,975
  
Title:
An open-label, multicenter, randomized phase 3 study of first-line encorafenib plus cetuximab w/ or w/o chemotherapy vs standard of care therapy
Source:
PFIZER-C4221015-BREAKWATER
Role:
PI
Dates:
06/30/2022 - Present
Direct Funds:
$24,792
  
Prior
Peer Review
Title:
A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion
Source:
NCTN LAPS
Role:
PI
Dates:
07/28/2010 - 04/18/2018
  
Title:
A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross- Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer
Source:
NCTN LAPS
Role:
PI
Dates:
11/28/2012 - 06/01/2013
  
Title:
A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
Source:
NCTN LAPS
Role:
PI
Dates:
01/20/2014 - 03/07/2016
  
Non-Peer Review
Title:
Modular Phase II Study To Link Targeted Therapy To Patients With Pathway Activated Tumors: Module 1 - BKM120 For Patients With PI3K-Activated Tumors
Source:
NOVARTIS-SIG-BKM120
Role:
PI
Dates:
04/11/2014 - 01/29/2016
Direct Funds:
$38,821
  
Title:
Modular Phase II Study To Link Targeted Therapy To Patients With Pathway Activated Tumors: Module 8 A? LEE011 For Patients With CDK4/6 Pathway Activated Tumors
Source:
NOVARTIS-SIG-LEE011
Role:
PI
Dates:
11/25/2014 - 11/03/2016
Direct Funds:
$52,148
  
Title:
A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Source:
CELGENE-ABI-007-ST-001
Dates:
05/11/2015 - 11/26/2018
Direct Funds:
$233,989
  
Title:
A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Flourouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Source:
MERCK-MK-3475-059
Role:
PI
Dates:
09/30/2015 - 03/06/2020
Direct Funds:
$38,029
  
Title:
A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine
Source:
MERCK-MK-3475-061
Role:
PI
Dates:
12/11/2015 - 06/13/2018
Direct Funds:
$61,063
  
Title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma
Source:
ASTELLAS-9785-CL-3021
Role:
PI
Dates:
07/01/2016 - 03/07/2018
Direct Funds:
$31,094
  
Title:
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Source:
MERCK-MK-3475-062
Role:
PI
Dates:
07/11/2016 - 04/28/2017
Direct Funds:
$53,095
  
Title:
Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) versus Placebo Plus BSC in Patients with Metastatic Gastric Cancer Refractory to Standard Treatments
Source:
TAIHO-TO-TAS-102-302
Role:
PI
Dates:
08/19/2016 - 08/21/2018
Direct Funds:
$29,471
  
Title:
An Open-Label, Multicenter Phase Ib Study of the Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination with Bevacizumab and/or Other Treatments in Patients with Solid Tumors
Source:
HOFFMANN-LAROCHE-GO30140
Role:
PI
Dates:
08/07/2017 - 07/22/2019
Direct Funds:
$161,468
  
Title:
Phase I Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab with Nivolumab in Unresectable Hepatocellular Carcinoma
Source:
UC-17-0578-HCC
Role:
PI
Dates:
04/26/2018 - 03/13/2019
Direct Funds:
$30,002
  
Title:
Phase 1/2 Study Of TAS-120 In Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
Source:
TAIHO-TPU-TAS-120-101
Role:
PI
Dates:
07/31/2018 - 11/30/2019
Direct Funds:
$46,206
  

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Chemotherapy for Pancreatic Cancer, HPB Didactic Lecture, Medical College of WI, 03/01/2012
Initial Experience with FOLFIRINOX in the neo-adjuvant setting for patients with Borderline Resectable Pancreatic Cancer, Division of Hematology and Oncology Research Meeting, Medical College of WI, 11/15/2012
Chemotherapy for Pancreatic Cancer Past, Present and Future Novel Treatment Sequencing, Pancreatic Cancer Symposium, Milwaukee Art Museum, Milwaukee, WI, 02/16/2013
Multimodality Treatment of Foregut Malignancies "Timing is Everything", GI ASCO update, Medical College of Wisconsin Alumni Center, 03/23/2013
Clinicopathologic Conference for the Internal Medicine Residents, Medical College of WI, 11/2013
Integration of Locoregional Therapy with Systemic Therapy in patients with metastatic Colorectal Cancer, HPB Didactic Lecture Series, Medical College of WI, 04/03/2014
Locally Advanced Pancreatic Cancer, HPB Didactic Lecture Series, MCW, 04/03/2014
Clinical Trials in the Pancreatic Cancer Program, Annual Cancer Center Scientific Retreat, Serb Hall, Milwaukee, 06/06/2014
Chemotherapy in the management of Pancreatic Cancer, Community Memorial Hospital, Menomonee Falls, WI, 08/29/2014 - 08/29/2017
Challenges in delivering FOLFIRINOX and Gemcitabine-Nab Paclitaxel, The Annual Pancreatic Cancer Symposium, Milwaukee Art Museum, Milwaukee, WI, 09/05/2014
Pancreatic Cancer Treatment Approaches, Pancreatic Cancer Action Network (PanCAN), Radisson Hotel, Milwaukee, WI, 10/01/2014
Role of Molecular Profiling in patients with metastatic Colorectal Cancer, The Symposium on Metastatic Colon Cancer, Milwaukee, WI, 05/01/2015
Molecular Classification of Pancreatic Cancer, HPB Didactic Lecture, Medical College of WI, 06/02/2016
Role of Molecular Markers and the Newest Tumor Board, Regional Therapies Symposium, Milwaukee, WI, 08/04/2016
Neuroendocrine Cancer -Subtypes, Natural History and Treatment, Didactic Lecture for the Interventional Radiology Fellows, Medical College of WI, 12/01/2016
GI ASCO Update 2017, Pancreatic Cancer Symposium, Milwaukee, WI, 01/27/2017
Treatment Sequencing in Localized Pancreas cancer, Pathology Grand Rounds, Froedtert and Medical College of Wisconsin, 10/12/2018
Treatment Sequencing in Localized Pancreas cancer, Transplant Surgery Grand Rounds, Froedtert and Medical College of Wisconsin, 12/04/2018
 
Regional
Treatment Sequencing for Gastric Cancer: Is there an ideal approach?, Invited Lecture at St. Agnes Hospital, Fon Du Lac, WI, 02/13/2014
Modern Metastatic Colorectal Cancer Management, Fox Valley Hematology/Oncology Group, Appleton, WI, 11/06/2014
Multi-modality Therapy for Management of Gastro-Esophageal malignancies: Optimal Treatment Sequencing, Invited lecture at St. Vincent Hospital, Green Bay, WI, 09/11/2015
Molecular profiling in GI Cancers, Invited lecture at the Spotlight on Peritoneal surface malignancies Conference, Kohler, WI, 08/04/2017
Treatment Sequencing in Localized Pancreas cancer, Aspirus Spring Oncology Forum, Wausau, WI, 04/27/2019
Pancreatic Ductal Adenocarcinoma "A Review of the Treatment Landscape", Pancreatic Cancer Translational Science Symposium, Milwaukee, WI, 10/25/2019
Updates in Colorectal Cancer, Annual Advances in Hematology and Oncology Symposium, Green Bay, WI, 10/26/2019
ASCO GI Updates, Milwaukee, WI, 01/31/2020
 
National
Sequencing Chemotherapy and Radioembolization in the treatment of metastatic Colorectal Cancer, Invited lecture for the Florida Interventional Specialists, Tampa, FL, 05/29/2014
Modern Metastatic Colorectal Cancer Management, Florida Fish Memorial Hospital, Orange City, Florida, 07/11/2014
Modern Metastatic Colorectal Cancer Management, Lankenau Hospital, Wynnewood, Pennsylvania, 10/13/2014
The Case for Integration of Locoregional Therapy with Systemic Therapy in metastatic Colorectal Cancer, Invited lecture at the Annual World Congress of Interventional Oncology (WCIO), New York, 05/06/2015 - 05/09/2016
The Case for Integration of Loco-regional Therapy with Systemic Therapy for Colorectal Liver Metastases, Invited Lecture at the Annual World Congress of Interventional Oncology (WCIO) metastatic Colorectal Cancer Plenary Session, Boston, MA, 06/09/2016 - 06/12/2016
NCCN Updates- Medical Oncology Perspective, Invited Lecture at the Society of Interventional Radiology Annual Meeting, Washington DC, 03/05/2017
Combining Intra-arterial Therapy with Chemotherapy for mCRC, Invited Lecture at the Society of Interventional Radiology Annual Meeting, Washington DC, 03/07/2017
Moderated the metastatic Colorectal Cancer session, the World Congress of Interventional Oncology Meeting, Boston, MA, 06/08/2017 - 06/11/2017
When Should IO Therapy Be Integrated into Systemic Therapy?, Invited lecture at the World Congress of Interventional Oncology Meeting, Boston, MA, 06/08/2017 - 06/11/2017
Invited Panelist for the metastatic Colorectal Cancer Tumor Board, The World Congress of Interventional Oncology Meeting, Boston, MA, 06/08/2017 - 06/11/2017
Y90 by lines of therapy: Can we justify administration of Y90 on earlier chemotherapy lines? NO: only on Trial, Society of Interventional Radiology Annual Meeting, Los Angeles, California, 03/19/2018
Treatment Sequencing in Localized Pancreas Cancer, Cancer Center Grand Rounds, University of Nebraska, Omaha, Nebraska, 01/21/2019
A Primer: Systemic Therapies in the Era of Molecular Subtyping, plenary session on Colorectal Liver Metastases at the Annual Society of Interventional Oncology Meeting, Boston, MA, 06/09/2019
What is Oligometastatic Disease.Plenary session on Lung Mets Comparative Effectiveness, Annual Society of Interventional Oncology Meeting, Boston, MA, 06/10/2019
 
International
Adjuvant and Neo-adjuvant Strategies for Colorectal Cancer, Invited Lecture at the Colorectal Continuing Medical Education Symposium, Thruvananthapuram, Kerala, India, 11/07/2015 - 11/08/2015
Limits of Systemic Therapies - Individualized Local Approaches, Invited Lecture at the European Conference on Interventional Oncology (ECIO), Dublin, Ireland, 04/17/2016 - 04/20/2016
Management of Metastatic Colorectal Cancer, Saint Paul Millennium Medical College, University of Addis Ababa, Addis Ababa, Ethiopia, 11/27/2017
Treatment Sequencing in Localized Gastro-Esophageal Cancer, Invited Lecture at Saint Paul Millennium Medical College, University o Addis Ababa, Addis Ababa, Ethiopia, 11/28/2017
Management of Metastatic Gastro-Esophageal Cancer, Invited Lecture at Saint Paul Millennium Medical College, University o Addis Ababa, Addis Ababa, Ethiopia, 12/01/2017
Treatment Sequencing in Localized Pancreas Cancer, Kochi Oncology Group Meeting, Kochi, Kerala, India, 08/11/2018
 

MEDICAL COLLEGE TEACHING ACTIVITIES:
Medical Student Education
11/16/2011 Choosing a career in Medical Oncology, Lecture for Medical Students
 
Resident and Fellow Education
07/01/2011 - Present Annual Didactic Lecture for Internal Medicine Residents on Colorectal Cancer
07/01/2011 - Present Annual didactic lecture for Hematology and Oncology Fellows on Gastro-Esophageal Malignancies
 

EXTRAMURAL TEACHING:
Medical Student Education
01/01/2013 - Present Preceptor for the M1/M2 Clinical Apprenticeship Course
07/01/2014 - Present Preceptor for the M4 Hematology and Oncology Ambulatory Clinic
 

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
Undergraduate Students
David Wittman, St. Norbert College, De Pere, WI, Clinic Preceptor/Mentor
Mitchell Depke, University of Wisconsin, Madison, Clinic Preceptor/Mentor
Sonali Srivastava, Cornell University, New York, Clinic Preceptor/Mentor
Arjun Ranade, - University of Wisconsin, Milwaukee, Clinic Preceptor/Mentor, Arjun Ranade???s work resulted in a poster presentation at GI ASCO 2015
 
Medical Students
Maahum Mehdi, Research Mentor, Abstracts -GI ASCO 2021, GI ASCO 2022, manuscript in preparation
Abhishek Janardan, Abstract submission in process
 
Clinical/Research Fellows
Shinoj P. Jayavalsan, MD, Posters at GI ASCO 2016 (Merit Award), Pancreas Club 2016
Arun Singavi, MD, Clinical/Research Mentor, Posters at ESMO 2017 (Merit Award), GI ASCO 2018, Manuscript ??? Journal of Oncology Practice, 2019
Shannon Schmidt, MD, Posters (2) ??? GI ASCO 2016
Ravi Narra, MD, Clinical/Research Mentor, Posters at GI ASCO 2018, AACR 2018
Kathleen Monahan, MD, Clinical/Research Mentor, Book Chapter in preparation
Kristen Corrao, Clinical/Research Mentor, Book Chapter in preparation
Narendranath Epperla, MD, Clinical/Research Mentor, Manuscript -Journal of Gastrointestinal Cancer, 2015
Thomas Giever, MD, Clinical/Research Mentor, Posters at AACR 2014, GI ASCO 2015, MCW Research Day poster award, 2014
Rekha Chandran, MD, Clinical/Research Mentor, Manuscript -JAMA Dermatology, 2015
Kathleen Hemauer, MD, Clinical Mentor
 
Residents
Lauren Jurkowski, Abstract ASCO 2021
Muthiah Chandrasekhar, Ongoing Research
Kaitlin Annunzio, Clinical/Research Mentor, Abstract GI ASCO 2020
 
Faculty
Gulrayz Ahmed, MD, Clinical/Research Mentor, Poster ??? GI ASCO 2021, manuscript in preparation
Bicky Thapa, MD, Poster ??? AACR 2021, manuscript in preparation
 

COMMUNITY SERVICE ACTIVITIES:
Sebastian Raclaw Abdominal Cancer Research Fund: Fundraising activity (`$25,000) by a grateful patient's family (dedicated to Dr. Turaga and me)
The McGinn Family donated ~ $37,500 for Pancreatic Cancer Research in 2019
Ellen's Icebreaker fund for gastric Cancer: Fundraising activity by a grateful patient's family. They have raised approximately $100,000 over the last 2 years
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. George B, Cote RJ, Datar RH; Nucleic Acids in Prognosis, National Medical Journal of India 14(3): 163-7, 2001
2. Chatterjee SJ, Datar RH, Youssefzadeh D, George B, Stein JP, Young L, Shi S-R, Gee C, Groshen SG, Skinner DG, Cote RJ; The combined effects of p53,p21 and pRb expression in the progression of bladder transitional cell carcinoma. Journal of Clinical Oncology 22 (6):1007-1013, 2004
3. Pagliarulo V, George B, Beil SJ, Groshen SG, Laird PW, Cai J, Willey JC, Cote RJ, Datar RH; Sensitivity and reproducibility of standardized competitive RT PCR for transcript quantification and its comparison with real-time RT-PCR. Molecular Cancer 3: 5-11, 2004
4. Chatterjee SJ, George B, Shi S-R, Datar RH, Goebell PJ, Fung YK, Jones PA, Cordon-Cardo C, Cote RJ; Hyperphosphorylation of pRB: a mechanism for Rb tumor suppressor pathway inactivation in bladder cancer. Journal of Pathology 203: 762-770, 2004
5. George B, Cote RJ, Datar RH; Does the decatenation G2 checkpoint suppress bladder carcinogenesis (Commentary). American Journal of Urology Review 2(7):347-350, 2004
6. Mitra AP, Almal AA, George B, Fry DW, Lenehan PF, Pagliarulo V, Cote RJ, Datar RH, Worzel WP;The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer 6:159, 2006
7. George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ,Groshen S, Stein J, Skinner D, Jones PA, Cote RJ;p53 Gene and Protein Status:The role of p53 Alterations in Predicting Outcome in Patients with Bladder Cancer. Journal of Clinical Oncology 25 (34):5352-5358, 2007
8. George B, Wirostko WJ, Connor TB, Choong NW. Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy. J Thorac Oncol. 2009 May;4(5):661-2.
9. Sukumaran S, George B, Parameshwaran NH, Drobyski WR; Posterior Reversible Encephalopathy Syndrome (PRES) in association with high dose steroids after autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 45: 779-780, 2010
10. Olteanu H, Harrington AM, George B, Hari PN, Bredeson C, Kroft SH. High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. Bone Marrow Transplantation. 2011 Apr 11. [Epub ahead of print]
11. George B, Kopetz S; Predictive and Prognostic Markers in Colorectal Cancer. Current Oncology Reports 13(3):206-15, 2011
12. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C.Survival Benefit Associated with Surgical Oophorectomy in Patients with Colorectal Cancer Metastatic to the Ovary. Clinical Colorectal Cancer. 11 (3): 191-194, 2012
13. Wilson JM, Groeschl R, George B, Turaga KK, Patel PJ, Saeian K, Gamblin TC. Ciliated hepatic cyst leading to squamous cell carcinoma of the liver - A case report and review of the literature. Int J Surg Case Rep. 2013;4(11):972-5. PMCID: PMC3825928
14. Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Clark Gamblin T, Turaga KK. Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. Ann Surg Oncol. 2014 Jan;21(1):240-7.
15. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014 Mar;19(3):266-74. PMCID: PMC3958454
16. Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Pappas SG, Gamblin, TC, Turaga KK. Management of acute cholecystitis in cancer patients: a comparative effectiveness approach. Surg Endosc - 2014 Apr 02
17. Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, Erickson B, Pappas SG, Gamblin TC, Turaga KK. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur. J. Cancer a?? 2014 Apr 29
18. Christians KK, Pilgrim CH, Tsai S, Ritch P, George B, Erickson B ,Tolat P, Evans DB. Arterial resection at the time of pancreatectomy for cancer. Surgery, 2014, May 03
19. Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC. Molecular profiling in gastric cancer: Examining potential targets for chemotherapy. Journal of Surgical Oncology, 2014 May 21
20. Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, Wiebe L, Christians K, Evans DB, Erickson B. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Radiotherapy and Oncology. 2014 October;113 (1):41- 6
21. Krepline AN, Christians KK, Duelge K, Mahmoud A, Ritch P, George B, Erickson BA, Foley WD, Quebbeman EJ, Turaga KK, Johnston FM, Gamblin TC, Evans DB, Tsai S. Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer. Journal of Gastrointestinal Surgery. November 2014 (11) 2016-2025
22. Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. HPB (Oxford). 2015 Feb;17(2):131-9
23. Humphrey SR, Hussain A, Chandran R, Wilson B, George B. An acute onset of acrokeratosis paraneoplastica. JAMA Dermatology, 2015 March 11.
24. Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC. Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. Cancer Biol Ther. 2015;16(5):764-9. PMCID: PMC4622996
25. Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC. Tumor Profiling of gastric and esophageal carcinoma reveal different treatment options. Cancer Biology and Therapy 2015 March 16:1-6
26. Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM, Clark Gamblin T. Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2015 Mar 17
27. Epperla N, George B. An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. Journal of Gastrointestinal Cancer, May 2015 (Epub)
28. Evans DB, George B, Tsai S. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced a?? definitions of increasing importance for the optimal delivery of multimodality therapy. Invited editorial for Annals of Surgical Oncology, June 2015 (Epub)
29. Fathi A, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Johnston FM, Evans DB, Tsai S. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J Gastrointest Oncol. 2015 Aug;6(4):418-29
30. Aldakkak M, Christians K, Krepline AN, George B, Ritch P, Erickson B, Johnston F; Evans DB, Tsai S. Pre-treatment CA 19-9 Does Not Predict the Response to Neoadjuvant Therapy in Patients with Localized Pancreatic Cancer. HPB (Oxford). August 2015
31. Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Oshima K, Christians KK, Evans DB, Tsai S. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery. August 2015
32. Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, Johnston FM, Gamblin TC, Turaga KK. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. PLoS One. 2015 Oct 8;10(10)
33. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 patients.Clinical Colorectal Cancer.2015 Dec 29 (Epub)
34. Tsai S, Christians KK, Ritch PS, George B, Khan AH, Erickson B, Evans DB. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. J Oncol Pract. 2016 Oct;12(10):915-923.
35. Christians KK, Hemler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB, Tsai S. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016. Oct 23 (Epub)
36. Krepline AN, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Evans DB, Tsai S. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? J Surg Oncol. 2016 Oct;114(5):581-586.
37. Rajamanickam ES, Christians KK, Aldakkak M, Krepline AN, Ritch PS, George B, Erickson BA, Foley WD, Aburajab M, Evans DB, Tsai S. Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. J Gastrointest Surg. 2017 Mar;21(3):496-505
38. Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A. Comprehensive Analysis of Hypermutation in Human Cancer. Cell. 2017 Nov 16;171(5):1042-1056.e10
39. Blitzer GC, Hall WA, Tsai S, Aldakkak M, Hellman RS, Evans DB, Christians KK, George B, Ritch PS, Erickson BA. Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer? Pract Radiat Oncol. 2017 Nov - Dec;7(6):e449-e45
40. Barnes CA, Krepline AN, Aldakkak M, Clarke CN, Christians KK, Khan AH, Hunt BC, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? J Gastrointest Surg. 2017 Nov;21(11):1793-1803.
41. Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018 10;268(4):610-619.
42. Chatzizacharias NA, Tsai S, Griffin M, Tolat P, Ritch P, George B, Barnes C, Aldakkak M, Khan AH, Hall W, Erickson B, Evans DB, Christians KK. Locally advanced pancreas cancer: Staging and goals of therapy. Surgery. 2018 Jan 10. pii: S0039-6060(17)30633-5.(Epub ahead of print)
43. Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hall WA, Erickson BA, Evans DB. Importance of Normalization of CA19-9 levels following Neoadjuvant Therapy in Patients with Localized Pancreatic Cancer. Ann Surg. 2018 Oct 11. doi: 10.1097/SLA.0000000000003049. [Epub ahead of print]
44. Xiong D, Wang Y, Singavi AK, Mackinnon AC, George B, You M. Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer. iScience. 2018 Nov 30;9:258-277. PMCID: PMC6234258
45. Shuen AY, Lanni S, Panigrahi GB, Edwards M, Yu L, Campbell BB, Mandel A, Zhang C, Zhukova N, Alharbi M, Bernstein M, Bowers DC, Carroll S, Cole KA, Constantini S, Crooks B, Dvir R, Farah R, Hijiya N, George B, Laetsch TW, Larouche V, Lindhorst S, Luiten RC, Magimairajan V, Mason G, Mason W, Mordechai O, Mushtaq N, Nicholas G, Oren M, Palma L, Pedroza LA, Ramdas J, Samuel D, Wolfe Schneider K, Seeley A, Semotiuk K, Shamvil A, Sumerauer D, Toledano H, Tomboc P, Wierman M, Van Damme A, Lee YY, Zapotocky M, Bouffet E, Durno C, Aronson M, Gallinger S, Foulkes WD, Malkin D, Tabori U, Pearson CE. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. J Clin Oncol. 2019 Jan 4: [Epub ahead of print].
46. Wong M, Kim J, George B, Eriksen C, Pearson T, Robbins J, Zimmerman MA, Hing JC.Downstaging Locally-Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study. Journal of Surgical Research. Accepted for publication April 2019.
47. Singavi A, Ramalingam V, George B. Etanercept for Treatment of Taxane-Induced Pneumonitis. Journal of Oncology Practice. June 20, 2019.
48. Shuen AY, Lanni S, Panigrahi GB, Edwards M, Yu L, Campbell BB, Mandel A, Zhang C, Zhukova N, Alharbi M, Bernstein M, Bowers DC, Carroll S, Cole KA, Constantini S, Crooks B, Dvir R, Farah R, Hijiya N, George B, Laetsch TW, Larouche V, Lindhorst S, Luiten RC, Magimairajan V, Mason G, Mason W, Mordechai O, Mushtaq N, Nicholas G, Oren M, Palma L, Pedroza LA, Ramdas J, Samuel D, Wolfe Schneider K, Seeley A, Semotiuk K, Shamvil A, Sumerauer D, Toledano H, Tomboc P, Wierman M, Van Damme A, Lee YY, Zapotocky M, Bouffet E, Durno C, Aronson M, Gallinger S, Foulkes WD, Malkin D, Tabori U, Pearson CE. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. J Clin Oncol. 2019 02 20;37(6):461-470.
49. Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.Surgery. 2019 Sep;166(3):277-285
50. Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunother Cancer. 2019 02 01;7(1):27. PMCID: PMC6359802
51. Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019 06;156(8):2242-2253.e4.
52. Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery. 2019 09;166(3):277-285.
53. Goldman JW, Waterhouse DM, George B, O'Dwyer PJ, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, Kelly K. Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With <i>nab</i>-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer. Front Oncol. 2019;9:1256. PMCID: PMC6901975
54. Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. J Immunother Cancer. 2019 01 24;7(1):18. PMCID: PMC6346512
55. Jariwalla NR, Khan AH, Dua K, Christians KK, Clarke CN, Aldakkak M, George B, Tutton S, Rilling W, Erickson B, Evans DB, Tsai S. Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol. 2019 Dec;26(13):4515-4521.
56. Wong M, Kim J, George B, Eriksen C, Pearson T, Robbins J, Zimmerman MA, Hong JC. Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: AA Prospective Pilot Study. J Surg Res. 2019 10;242:23-30.
57. Singavi AK, Ramalingam V, George B. Etanercept for Treatment of Taxane-Induced Pneumonitis. J Oncol Pract. 2019 10;15(10):556-557.
58. Barnes CA, Aldakkak M, Clarke CN, Christians KK, Bucklan D, Holt M, Tolat P, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Front Oncol. 2020 Apr 17;10:500. doi: 10.3389/fonc.2020.00500. eCollection 2020
59. Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? J Gastrointest Surg. 2020 02;24(2):235-242.
60. Wittmann D, Hall WA, Christians KK, Barnes CA, Jariwalla NR, Aldakkak M, Clarke CN, George B, Ritch PS, Riese M, Khan AH, Kulkarni N, Evans J, Erickson BA, Evans DB, Tsai S. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Front Oncol. 2020;10:460. PMCID: PMC7175033
61. Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ort?- G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Holter Chakrabarty J, Saber W. The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biol Blood Marrow Transplant. 2020 06;26(6):1137-1143. PMCID: PMC7367282
62. Krepline AN, Geurts JL, Akinola I, Christians KK, Clarke CN, George B, Ritch PS, Khan AH, Hall WA, Erickson BA, Griffin MO, Evans DB, Tsai S. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. HPB (Oxford). 2020 Apr 27. pii: S1365-182X(20)30109-X. doi: 10.1016/j.hpb.2020.03.022. [Epub ahead of print]
63. George B. Safety & Efficacy of Trifluridine/Tipiracil in Metastatic Gastric Cancer: LWW, 2020.
64. Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, Waterhouse DM, Guiterrez M, Parikh A, Jain R, Carrizosa DR, Soliman HH, Lila T, Reiss DJ, Pierce DW, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, O'Dwyer PJ. Open-label, Phase I Study of Nivolumab Combined with <i>nab</i>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clin Cancer Res. 2020 09 15;26(18):4814-4822.
65. Barnes CA, Aldakkak M, Clarke CN, Christians KK, Bucklan D, Holt M, Tolat P, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Value of Pretreatment <sup>18</sup>F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Front Oncol. 2020;10:500. PMCID: PMC7180175
66. Krepline AN, Geurts JL, Akinola I, Christians KK, Clarke CN, George B, Ritch PS, Khan AH, Hall WA, Erickson BA, Griffin MO, Evans DB, Tsai S. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. HPB (Oxford). 2020 12;22(12):1745-1752.
67. Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Ann Surg. 2020 04;271(4):740-747.
68. Ilson DH, Tabernero J, Prokharau A, Arkenau HT, Ghidini M, Fujitani K, Van Cutsem E, Thuss-Patience P, Beretta GD, Mansoor W, Zhavrid E, Alsina M, George B, Catenacci D, McGuigan S, Makris L, Doi T, Shitara K. Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. JAMA Oncol. 2020 Jan 01;6(1):e193531. PMCID: PMC6802061
69. Stein A, Strong E, Clark Gamblin T, Clarke C, Tsai S, Thomas J, George B, Mogal H. Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. Ann Surg Oncol. 2020 Jan;27(1):85-97.
70. Chung J, Maruvka YE, Sudhaman S, Kelly J, Haradhvala NJ, Bianchi V, Edwards M, Forster VJ, Nunes NM, Galati MA, Komosa M, Deshmukh S, Cabric V, Davidson S, Zatzman M, Light N, Hayes R, Brunga L, Anderson ND, Ho B, Hodel KP, Siddaway R, Morrissy AS, Bowers DC, Larouche V, Bronsema A, Osborn M, Cole KA, Opocher E, Mason G, Thomas GA, George B, Ziegler DS, Lindhorst S, Vanan M, Yalon-Oren M, Reddy AT, Massimino M, Tomboc P, Van Damme A, Lossos A, Durno C, Aronson M, Morgenstern DA, Bouffet E, Huang A, Taylor MD, Villani A, Malkin D, Hawkins CE, Pursell ZF, Shlien A, Kunkel TA, Getz G, Tabori U. DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. Cancer Discov. 2021 05;11(5):1176-1191. PMCID: PMC8223607
71. Mora J, Krepline AN, Aldakkak M, Christians KK, George B, Hall WA, Erickson BA, Kulkarni N, Evans DB, Tsai S. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. Am J Surg. 2021 07;222(1):10-17.
72. Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M. Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. Hematol Oncol Stem Cell Ther. 2021 Mar;14(1):65-70. PMCID: PMC7543702
73. Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA, Kulkarni N, Erickson BA, Evans DB, Tsai S. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. Surgery. 2020 09;168(3):440-447.
74. Krepline AN, Geurts JL, George B, Kamgar M, Madhavan S, Erickson BA, Hall WA, Griffin MO, Evans DB, Tsai S, Kim RY. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Surgery. 2021 03;169(3):629-635.
75. Hall WA, Kamgar M, Erickson BA, Ponce SB, Tsai S, Nevalainen MT, Christians KK, George B, Dua KS, Khan AH, Evans DB, Azmi AS. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Cancer Metastasis Rev. 2021 09;40(3):879-889. PMCID: PMC8767496
76. Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Ann Surg Oncol. 2021 Apr;28(4):2246-2256.
77. George B. Precision Medicine and Pancreatic Cancer. Surg Oncol Clin N Am. 2021 10;30(4):693-708.
78. Kamgar M, Chakrabarti S, Shreenivas A, George B. Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. Surg Oncol Clin N Am. 2021 10;30(4):673-691.
79. Luo J, Tong L, Crotty BH, Somai M, Taylor B, Osinski K, George B. Telemedicine Adoption during the COVID-19 Pandemic: Gaps and Inequalities. Appl Clin Inform. 2021 08;12(4):836-844. PMCID: PMC8426040
80. Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 09;22(9):1290-1300.
81. Stachowiak S, Jacquart A, Zimmermann MT, George B, Dong H, Geurts JL. Germline evaluation of patients undergoing tumor genomic profiling: An academic cancer center's experience with implementing a germline review protocol. J Genet Couns. 2021 06;30(3):900-910.
82. George B, Kent M, Surinach A, Lamarre N, Cockrum P. The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Front Oncol. 2021;11:754687. PMCID: PMC8522478
83. George B, Kurzrock R. Progression-free survival 2: Is it ready for prime time? Cancer. 2022 04 01;128(7):1361-1362.
84. Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone SC, Alsafwani N, Liu ZA, Karsaneh OAA, Soleimani S, Ladany H, Chen D, Zatzman M, Cabric V, Nobre L, Bianchi V, Edwards M, Sambira Nahum LC, Ercan AB, Nabbi A, Constantini S, Dvir R, Yalon-Oren M, Campino GA, Caspi S, Larouche V, Reddy A, Osborn M, Mason G, Lindhorst S, Bronsema A, Magimairajan V, Opocher E, De Mola RL, Sabel M, Frojd C, Sumerauer D, Samuel D, Cole K, Chiaravalli S, Massimino M, Tomboc P, Ziegler DS, George B, Van Damme A, Hijiya N, Gass D, McGee RB, Mordechai O, Bowers DC, Laetsch TW, Lossos A, Blumenthal DT, Sarosiek T, Yen LY, Knipstein J, Bendel A, Hoffman LM, Luna-Fineman S, Zimmermann S, Scheers I, Nichols KE, Zapotocky M, Hansford JR, Maris JM, Dirks P, Taylor MD, Kulkarni AV, Shroff M, Tsang DS, Villani A, Xu W, Aronson M, Durno C, Shlien A, Malkin D, Getz G, Maruvka YE, Ohashi PS, Hawkins C, Pugh TJ, Bouffet E, Tabori U. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med. 2022 01;28(1):125-135. PMCID: PMC8799468
 
Books, Chapters, and Reviews
1. George B, Datar RH, Cote RJ; Molecular biology of bladder cancer : Cell Cycle Alterations. Chapter 10 (pages 107-122), Textbook of Bladder Cancer, Taylor & Francis Ltd, 2006
2. Tsai S, George B, Christians KK, Evans DB. Neoadjuvant chemotherapy and radiochemotherapy: is there a survival advantage for pancreatic cancer patients. In Beger HG, Nakao A, Neoptolemos JP, Peng SY, Sarr MG, eds. Pancreatic Cancer, Cystic Neoplasms, and Endocrine Tumors: Diagnosis and Management. Oxford: Wiley-Blackwell, 2015.
3. Kosinski L, George B, Turaga KK, Johnstone CA, Mahmoud M. Colon and Rectal Cancer. The American Cancer Society's Oncology in Practice: Clinical Management. 2018: 124-148.
4. Christians KK, Younan G, George B, Tsai S, Evans DB. Resection Versus Chemotherapy for Metastatic Neuroendocrine Tumors of the Pancreas. Difficult Decisions in Endocrine Surgery: Springer, 2018:441-457.
5. George B. Molecular Profiling in Pancreatic Ductal Adenocarcinoma. Management of Localized Pancreatic Cancer. Springer, Cham 2019. 133-141.
6. George B, Ritch PS. Delivery of Neoadjuvant Versus Adjuvant Therapy in Localized Pancreatic Cancer. Management of Localized Pancreatic Cancer. Springer, Cham.2019.67-84
7. George B. Small Bowel and Appendiceal Cancers. Handbook of Targeted Cancer Therapy and Immunotherapy. LWW (in press)
8. George B. Peritoneal Cancers. Handbook of Targeted Cancer Therapy and Immunotherapy. LWW (in press)
 
Abstracts
1. Goebell PJ, George B, Brands FH, Datar RH, Shi S-R, Stein JP, Cote RJ: p21WAF/Cip1, p27Kip1 and p53 expression in bladder cancer (Seminar). 18th Annual Meeting of the Urological Research Society, Izmir, Turkey, September13-15, 2001
2. George B, Goebell PJ, Datar RH, Cai J, Brands FH, Young LL, Shi S-R, Groshen SG, Stein JP, Skinner DG, Cote RJ: p21Waf/Cip1, p27Kip1and p53; expression and impact on clinical outcome in invasive bladder cancer (Seminar). 38th Annual Meeting of the American Society Of Clinical Oncology, Orlando, Florida, May18-21, 2002
3. George B, Datar RH, Wu L, Beil SJ, Patten N, Cai J, Groshen SG, Cote RJ: Functional Role of p53 in invasive bladder cancer: A correlation between gene status by GeneChip analysis and protein expression by Immunohistochemistry (Poster). Affymetrix User Group Meeting, SanDiego May 6-7, 2003
4. Pagliarulo V, George B, Groshen SG, Laird PW, Cai J, Willey J, Datar RH, Cote RJ; Sensitivity and reproducibility of standardized competitive RT PCR for transcript Quantification and its comparison with real-time RT-PCR (poster). 94th Annual Meeting of the American Association for Cancer Research, Washington DC, July 11-14, 2003
5. George B, Pagliarulo V, Beil SJ, Buckley J, Datar RH, Cote RJ; Molecular Characterization of Bladder cancer cell lines by quantitative transcript profiling using the StaRT PCR assay (poster). 94th Annual Meeting of the American Association for Cancer Research, Washington DC, July 11-14, 2003
6. George B, Datar RH, Wu L, Beil SJ, Patten N, Cai J, Groshen SG, Cote RJ: Complete p53 Multi- exon Sequencing by GeneChip Complements Use of p53 Immunohistochemistry for Prediction of Clinical Outcome in Invasive Bladder Cancer (poster). 95th Annual Meeting of the American Association for Cancer Research, Orlando, Florida, March27-31, 2004
7. Beil SJ, George B, Wu L, Cai J, Patten N, Young L, Groshen SG, Datar RH, Cote RJ; Comparison of p53 genotype and phenotype:Site of mutation predicts outcome in patients with bladder cancer. American Society of Clinical Oncology. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 9561
8. Oettel KR, Joseph R, George B, Lee JA, Mathiason MA, Meyer L, Go RS; Compliance to National Comprehensive Cancer Network guidelines in patients with newly diagnosed small cell lung cancer at a community cancer center. American Society of Clinical Oncology. Vol 25, No. 18S (June 20 Supplement), 2007: 17064
9. George B, Simhan S, Lee JA, Mathiason MA, Go RS; Conflicts of interest among articles published in the Journal of Clinical Oncology. American Society of Clinical Oncology. Vol 25, No. 18S (June 20 Supplement), 2007: 6633
10. Olteanu H, Harrington A, George B, Bredeson C, Parameshwaran NH, Kroft S; High Prevalence of Dapsone Induced Oxidant Hemolysis in North American Stem cell Transplant Recipients with Glucose-6-Phosphate Dehydrogenase Deficiency. American Society of Hematology (Blood) November 2009; 114:3314
11. Hassabo HM, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). J Clin Oncol 29: 2011 (suppl; abstr 3618)
12. George B, You N, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR; Survival Advantage Associated with Palliative Oophorectomy in Patients with Metastatic Colorectal Cancer to the Ovaries: A Single Institution Retrospective Analysis. Abstract ID 539, Gastrointestinal Cancers Symposium, San Francisco, California, January 20- 22, 2011
13. George B, You N, Viswanathan C, Wen S, Baladandayuthapani V, Overman MJ, Kee BK, Kopetz S, Eng C, Garrett CR; Palliative Oophorectomy in Patients with Metastatic Colorectal Cancer to the Ovaries. Poster ID P156, Society of Surgical Oncology Annual Cancer Symposium, San Antonio, Texas March 2-5, 2011
14. George B, Estrella J, Machado,KK Ferrarotto R, Hoff PM, Rashid A, Kopetz, S. High-grade neuroendocrine carcinomas (HGNECs) of the colon and rectum: A single-institution retrospective analysis. J Clin Oncol 29: 2011 (suppl; abstr e14040)
15. Hassabo H, Hassan M, George B, Wen S, Baladandayuthapani V, Kopetz S, Fogelman DR, Kee BK, Eng C, Garrett CR. Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). J Clin Oncol 29: 2011 (suppl 4; abstr 507)
16. Kharofa JR, Kelly T, Wood C, George B, Tsai S, Ritch P, Wiebe L, Christians K, Evans D, Erickson B. Neoadjuvant Chemoradiation with IMRT in Resectable and Borderline Resectable Pancreatic Cancer (PCa). ASTRO 2012
17. Kharofa J, Kelly T, Ritch P, George B, Wiebe LA, Thomas JP, Christians K, Evans DB, Erickson B. 5-FUleucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic Cancer 2012 GI ASCO
18. Kharofa J, Kelly TR , Ritch PS, George B, Wiebe LA, Thomas JP, Christians KK, Evans DB, Erickson B. 5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer. J Clin Oncol 30, 2012 (suppl; abstr e14613).
19. Kharofa J, Kelly T, Wood C, George B, Tsai S, Ritch P, Wiebe L, Christians K, Evans D, Erickson B. Local control in Resectable and Borderline Resectable Pancreatic Cancer Treated with Preoperative Chemoradiation Using IMRT or Chemotherapy Alone. 2013 ASCO-ASTRO 2013 January 24-26, 2013
20. Christians K, Tsai S, Mahmoud A, Ritch P, Thomas J, Wiebe L, Kelly T, Erickson B, Wang H, Evans D, George B. Neoadjuvant FOLFIRINOX For Borderline Resectable Pancreas Cancer - A New Treatment Paradigm? Association of VA Surgeons Meeting, Milwaukee, April 21, 2013
21. George B, Ritch PS, Thomas JP, Wiebe LA, Mahmoud A, Christians KK, Pappas SG, Turaga KK, Quebbeman EJ, Gamblin TC, Erickson B, Kelly TR, Evans DB, Tsai S. Utility of pretreatment serum carcinoembryonic antigen (CEA) level in patients with localized pancreatic cancer (LPCa). Pancreas Club 2013
22. Miura JT, Krepline A, Duelge KD, George B, Ritch PS, Erickson B, Thomas JP, Mahmoud A, Quebbeman EJ, Turaga KK, Johnston FM, Christians KK, Gamblin TC, Evans DB, Tsai S. Neoadjuvant therapy for pancreatic cancer in patients older than age 75. GI ASCO 2014
23. Longo JM, Siker ML, George B, Kosinski L, Ludwig KA, Otterson M, Thomas JP, Wiebe LA, Erickson B. Helical tomotherapy with concurrent chemotherapy in the treatment of anal canal carcinoma: A review of clinical outcomes at a tertiary referral center. GI ASCO 2014
24. Conte B, George B, Dasari A, Overman MJ, Estrella J, Jiang Z, Machado K, Mello CL, Ferrarotto R, Hoff PM, Yao JC, Rashid A, Kopetz S. Colorectal high-grade neuroendocrine carcinoma: A single institution experience. GI ASCO 2014
25. Krepline, AN, Aldakkak, M, George B, Ritch, PS, Erickson, BA, Johnston, F, Christians, KK, Evans, DB, Tsai, S. Importance of Preoperative CA 19-9 Levels in Patients with Localized Pancreatic Cancer Treated with Neoadjuvant Therapy. Society of Surgical Oncology, 2014
26. Aldakkak, M, Christians, KK, Krepline, AN, George B, Ritch, PS, Erickson, BA, Johnston, F, Evans, DB, Tsai, S. Pretreatment Serum CA 19-9 Levels in Patients with Localized Pancreatic Cancer Treated with Neoadjuvant Therapy. Society of Surgical Oncology, 2014
27. Giever T, Ritch P, Thomas J, Wiebe L, Haasler G, Gasparri M, Johnstone D, Johnstone C, Gore E, George B. A combination of Cisplatin, Irinotecan, and Paclitaxel (CIP) as frontline treatment of patients with metastatic Esophageal Cancer (mEC) AACR 2014
28. Tsai S, Christians KK, Dua K, Khan A, Oh Y, George B, Ritch P, Erickson BA, Hunt B, Rao A, Mackinnon AC, Evans DE. Rapid immunohistochemical analysis of pancreatic cancer cytology from endoscopic ultrasound guided fine needle aspirates. 2014 AACR Meeting, New Orleans
29. Amini, A, Krepline, AN, Mahmoud, A, George B, Ritch, PS, Erickson, BA, Thomas, JP, Quebbeman, EJ, Turaga, KK, Johnston, F, Gamblin, TC, Christians, KK, Evans, DB, Tsai, S. Feasibility of Resection after Induction Therapy for Locally Advanced Pancreatic Cancer. Poster Presentation 2014 SSO Meeting, Phoenix, AZ
30. Miura, J, Krepline, AN, Deluge, J, George B, Ritch, PS, Erickson, BA, Thomas, JP, Mahmoud, A, Quebbeman, EJ, Turaga, KK, Johnston, F, Christians, KK, Gamblin, TC, Evans, DB, Tsai, S. Neoadjuvant Therapy for Pancreatic Cancer in Patients > age 75. Poster Presentation 2014 SSO Meeting, Phoenix, AZ
31. Heimler, JW, Krepline, AN, George B, Ritch, PS, Erickson, BA, Johnston, FM, Christians, KK, Evans, DB, Tsai, S. Survival Outcomes of Patients with Resectable Pancreatic Cancer Receiving Neoadjuvant Therapy. WI Surgical Meeting 2014
32. Krepline, AN, George B, Ritch, PS, Erickson, BA, Thomas, JP, Mahmoud, A, Quebbeman, EJ, Turaga, KK, Johnston, F, Gamblin, TC, Christians, KK, Evans, DB, Tsai, S. Prophylactic anticoagulation for superior mesenteric vein or portal vein narrowing/occlusion in borderline resectable pancreatic adenocarcinoma patients. Poster Presentation 2014 AHPBA Meeting, Miami, FL
33. Krepline, AN, Aldakkak M, George B, Ritch, PS, Erickson, BA, Johnston, FM, Christians, KK, Evans, DB, Tsai, S. Importance of Preoperative CA19-9 levels in Patients with Localized Pancreatic Cancer Treated with Neoadjuvant Therapy. SSO 2015 Houston. Oral Presentation
34. Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson EA, Johnston FM, Evans DB, Tsai S. Pre-treatment CA19-9 does not predict the response to Neoadjuvant therapy in patients with Localized Pancreatic Cancer March 2015 AHPBA Miami, FL
35. Miura TJ, Johnston FM, Tsai S, George B, Thomas JP, Christians KK, Turaga K, Pawlik TM, Ga,blin C. Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy. GI ASCO, 2015
36. Giever T, Ranade A, Thomas JP, Ritch P, Wiebe L, Haasler G, Gasparri M, Johnstone D, Gore E, Johnstone C, Dua K, Khan A, Oh Y, George B. Utility of invasive staging procedures in patients (pts) with localized esophageal cancer. GI ASCO, 2015
37. Miura, J, Aldakkak, MA, Krepline, AN, George B, Ritch, PS, Erickson, BA, Johnston, FM, Christians, KK, Evans, DB, Tsai S. Gender-based Differences in Survival Among Patients with Localized Pancreatic Cancer. Soc Black Acad Surg 2015, Chapel Hill, NC. Oral Presentation
38. D Waterhouse, M Gutierrez, T Bekaii-Saab, W DeRosa, Z Wainberg, George B, C Duval Fraser, A Ko, DW Pierce, S Stergiopoulos, H Soliman Nab-paclitaxel (nab-P) plus nivolumab (Nivo) in human epidermal growth factor receptor 2 (HER2)a??negative recurrent metastatic breast cancer (MBC). CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015, San Antonio, TX
39. Tsai S, Ritch PS, Erickson B, George B, Johnston FM, Mackinnon AC, Evans DB, Christians KK. Rapid immunohistochemical analysis of pancreatic cytology from endoscopic ultrasound-guided fine-needle aspirates: A prospective clinical trial. GI ASCO, 2016
40. Chrabaszcz S, Rajeev R, Klooster B, Chinn A, Gamblin TC, Johnston FM, George B, Banerjee A, Turaga K. Conversion to resectability in unresectable metastatic colorectal cancer chemotherapy (mCRC) trials. GI ASCO, 2016
41. Firdaus I, Waterhouse DM, Gitierrez, M, Wainberg, ZA, George B, Kelly K, Bekaii-Saab TS, Carrizosa DR, Soliman HH, Fraser CD, Ko A, Pierce DW, Manax VG, Stergiopoulos, SG, Hochster, HH. nab-paclitaxel (nab-P) + nivolumab (Nivo) A? gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC). GI ASCO, 2016
42. Schmidt S, Pattali S, Durkal V, Ritch P, Thomas JP, Erickson B, Christians K, Tsai S, Evans D, George B. Can the sequence of chemotherapy regimens influence outcome in patients with Metastatic Pancreatic Adenocarcinoma (MPAC)? GI ASCO 2016
43. Pattali S, Schmidt S, Durkal V, Ritch P, Thomas JP, Erickson B, Christians K, Tsai S, Evans D, George B. Can Response to treatment predict outcome in patients with Metastatic Pancreatic Adenocarcinoma (MPAC)? GI ASCO 2016 (Merit Award)
44. Schmidt S, Pattali S, Durkal V, Ritch P, Thomas JP, Erickson B, Christians K, Tsai S, Evans D, George B. Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and Gemcitabine + nab-paclitaxel (NabG). GI ASCO 2016
45. Barnes, CA, Aldakkak, M, Christians KK, Ritch PS, George B, Johnston FM, Erickson BA, Tolat P, Foley WD, Evans DB,Tsai, S. Impact of Treatment Sequencing on Sites of First Recurrence in Patients with Localized Pancreatic Cancer. SSAT 2016, San Diego, CA
46. Barnes CA, Aldakkak M, Christians KK, Ritch PS, George B, Johnston FM, Erickson BA, Hagan C, Oshima K, Evans DB, Tsai S. Impact of Number of Regional Lymph Node Metastasis in Patient with Localized Pancreatic Cancer Following Neoadjvuant Therapy. April 2016. Assoc of VA Surgeons. Virginia Beach, VA
47. D Waterhouse, George B, M Gutierrez, G Otterson, A Ko, TJ Ong, N Trunova, K Kelly. Phase I Study of Nivolumab + nab-Paclitaxel + Carboplatin in Advanced Non-Small Cell Lung Cancer: Safety and Efficacy Results. AACR Special Conference on Pancreatic Cancer. May 12-15, 2016, Orlando, FL.
48. Barnes, CA, Aldakkak, M, Christians KK, Ritch PS, George B, Johnston FM, Erickson BA, Tolat P, Foley WD, Evans DB, Tsai, S. Impact of Treatment Sequencing on Sites of First Recurrence in Patients with Localized Pancreatic Cancer. May 2016 Pancreas Club. San Diego, CA
49. Pattali S, Sreenivasan J, Premnath N, Schmidt S, Durkal V, Ritch P, Thomas JP, Erickson B, Christians K, Tsai S, Evans D, George B. Retrospective review of efficacy and dose intensity of second-line (SL) Nab-paclitaxel plus gemcitabine (NabG) for patients with metastatic pancreatic adenocarcinoma (MPAC) after first-line (FL) FOLFIRINOX (FFX). Pancreas Club Annual Meeting, May 20-21, 2016, San Diego, CA
50. Waterhouse, D; Gutierrez, M; Bekaii-Saab, T; DeRosa, W; Wainberg, Z; George B; Fraser, C Duval; Ko, A; Pierce, DW; Stergiopoulos, S; Abstract OT1-01-07: nab-paclitaxel (nab-P) plus nivolumab (Nivo) in human epidermal growth factor receptor 2 (HER2)a??negative recurrent metastatic breast cancer (MBC): AACR, 2016.
51. Barnes CA, Aldakkak M, Christians KK, Ritch PS, George B, Johnston FM, Erickson BA, Hagan C, Oshima K, Evans DB, Tsai S. Impact of Number of Regional Lymph Node Metastasis in Patient with Localized Pancreatic Cancer Following Neoadjvuant Therapy. May 2016 Pancreas Club, San Diego, CA
52. George B, Kelly, Karen; Ko, Amy; Soliman, Hatem; Trunova, Nataliya; Wainberg, Zev; Waterhouse, David; O'Dwyer, Peter; Phase i study of nivolumab+ nab-paclitaxel in solid tumors: Preliminary analysis of the non-small cell lung cancer cohort: Track: Advanced nsclc. Journal of Thoracic Oncology. 2016;11: S211-S212.
53. Paul Rajamanickam ES, Christians KK, Krepline AN, Aldakkak M, George B, Ritch PS, Erickson BA, Evans, DB, Tsai S. Poor Glycemic Control is Associated with Failure to Complete Neoadjvuant Therapy and Surgery in Patients with Localized Pancreatic Cancer. May 2016 57th Annual meeting of the Society for Surgery of the Alimentary Tract. Plenary Session. San Diego, CA
54. Hall, WA; Paulson, ES; Vistocky, A; Tsai, S; Koay, EJ; Knechtges, PM; Evans, D; Christians, K; Ritch, P; George B; Pancreatic Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) Radiomic Metrics Correlate With Pathologic Molecular Markers: An Exploratory Analysis. International Journal of Radiation Oncology, Biology, Physics. 2016;96: E178-E179.
55. George B, M Gutierrez, K Kelly, A Ko, HH Soliman, N Trunova, ZA Wainberg, D Waterhouse, P Oa??Dwyer, H Hochster. Phase 1 study of nivolumab (nivo) + nab-paclitaxel (nab-P) in solid tumors: preliminary analysis of pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts. Accepted for ESMO 2016, October 7-11, Copenhagen, Denmark
56. Wainberg, ZA; George B; Goldman, JW; Hochster, HS; Kelly, K; Ko, A; O'Dwyer, PJ; Trunova, N; Waterhouse, D; Soliman, HH; Interim results from the phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) in pancreatic cancer (PC), non-small cell lung cancer (NSCLC), and metastatic breast cancer (mBC). European Journal of Cancer: ELSEVIER SCI LTD THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB a?|, 2016:S103-S103.
57. Wainberg, Zev A; Hochster, Howard S; George B; Gutierrez, Martin; Johns, Mark Emery; Chiorean, E Gabriela; Kwak, Eunice Lee; Kalyan, Aparna; Manax, Victoria; Ye, Moncy; Phase I study of nivolumab (nivo)+ nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer (NSCLC) cohorts. Annals of Oncology. 2016;27: vi363.
58. Goldman JW, George B, Gutierrez M, Ko A, Oa??Dwyer PJ, Otterson GA, Soliman HH, Trunova N,. Waterhouse DM, Kelly K .Interim Results From the Phase I Study of Nivolumab + nab-Paclitaxel + Carboplatin in Non-Small Cell Lung Cancer. IASLC 17th World Conference on Lung Cancer, December 4-7, 2016, Vienna, Austria.
59. Kharofa, JR; Barnes, C; Mackinnon, A; George B; Ritch, P; Christians, K; Evans, D; Erickson, BA; Correlation of SMAD4 expression in pretreatment cytologic specimens and postneoadjuvant treatment surgical specimens in patients with pancreatic cancer. International Journal of Radiation Oncology, Biology, Physics. 2016;96: S141.
60. Jeong SY, Aldakkak M, Ahn K, Huang C, Christians KK, EricksonBA, Ritch PS, George B, Evans DB, Tsai S. Prognostic Nomogram for Patients with Operable Pancreatic Cancer Treated with Neoadjuvant Therapy. February 2017 12th Annual Academic Surgical Congress. Las Vegas, NV
61. Bahary N, He J, Bailey M, Zhong S, Li G, Young L, Singhi A, Stephens P, Ali SM, Singal G, Betzig Schrock A, Chung J, Ross Jeffery, Miller V, George B. Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with pancreatic ductal adenocarcinoma (PDA). GI ASCO, 2017
62. Singhi, AD; Greenbowe, J; Chung, J; Bailey, M; Bahary, N; Zeh, HJ; Brand, RE; Stephens, P; Ross, J; Miller, V;Comprehensive Genomic Profiling of 3426 Pancreatic Ductal Adenocarcinomas Identifies a Subset of Patients With Potentially Targetable Alterations. PANCREAS: LIPPINCOTT WILLIAMS & WILKINS TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA a?|, 2017:1436-1436.
63. Blitzer G, Tsai S, Aldakkak M, Hellman R, Evans DB, Christians KK, George B, Ritch PS, Hall WA, Erickson, B. Should functional renal scans be obtained prior to upper abdominal radiation for pancreatic cancer? GI ASCO, 2017
64. Wainberg ZA, Hochster HS, George B, Gutierrez M, Johns ME, Chiorean GE, Kwak EL, Kalyan A, Manax V, Ye M, Chen T, Trunova N, O'Dwyer PJ. Phase I study of nivolumab (nivo) + nab- paclitaxel (nab-P) A? gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts. GI ASCO, 2017
65. George B, Bailey M, Schrock AB, Thorpe L, Gay LM, Ritch PS, Thomas JP, Erickson B, Tsai S, Christians KK, Evans DB, Stephens PJ, Miller VA, Ross JS, Singhi AD, Ali SM. Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC). GI ASCO, 2017
66. Bailey M, Ali SM, Schrock AB, Klempner SJ, George B, Lipson D, He J, Miller VA, Stephens P, Ross JS. Comprehensive genomic profiling (CGP) of esophageal and tubular GI tumors to identify frequencies of ErbB family member amplification with therapeutic implications. GI ASCO, 2017
67. Wittmann D, Aldakkak M, Rajamanickam EP, Christians KK, Aburajab M, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S. Impact of Perioperative Changes in CA19-9 Levels in Patients with Resectable and Borderline Resectable Pancreatic Cancer. April 2017 Americas Hepato-Pancreato-Biliary Association Annual Meeting. Miami Beach, FL
68. Jeong SY, Aldakkak M , Ahn K, Huang C, Christians KK, EricksonBA, Ritch PS, George B, Evans DB, Tsai S. Preoperative Nomogram to Predict Survival for Patients with Resectable and Borderline Resectable Pancreatic Cancer. April 2017 Americas Hepato-Pancreato-Biliary Association Annual Meeting. Miami Beach, FL
69. Barnes C, Aldakkak M, Christians K, Khan A H, Oshima K, Ritch P, George B, Hall W, Erickson B, Evans D, Tsai S. Impact of Nodal Status on Adjuvant Therapy for Patients with Localized Pancreatic Cancer Treated with Neoadjuvant Therapy. DDW, 2017
70. Durno C, Aronson M, Edwards M, Ling S, Larouche V, Bronsema A, Osborn M, Stearns D, Cole K, Oren M, Opocher E, Mason G, Thomas G, Sabel M, George B, Ziegler D, Lindhorst S, Magimairajan V, Laperriere N, Samuel D, Bouffet E, Tabori U. Immune Check Point Inhibitor Treatment for Young Patients with Hypermutant Cancers. DDW, 2017
71. Bahary B, He J, Bailey M, Zhong S, Li G, Young L, Singhi A, Stephens P, Mahamad Ali S, Singal G, Schrock A, Chung J, Ross J, Miller V, George B. Genomic Profiling of Circulating Tumor DNA (ctDAN) From Patients (pts) with Pancreatic Ductal Adenocarcinoma (PDA). ASCO Annual Meeting, 2017, June 2-6, 2017 Chicago, IL J Clin Oncol 35, 2017 (suppl; abstr 4128).
72. Aldakkak, M; Tsai, S; George, B; Ritch, PS; Dua, K; Tolat, P; Hall, WH; Erickson, BA; Evans, DB; Christians, KK. Survival of borderline resectable pancreatic cancer patients receiving neoadjuvant therapy and surgery. HPB. 2017;19: S96-S97.
73. Chad Barnes, Mohammed Aldakkak, Kathleen K. Christians, Parag Tolat, Paul S. Ritch, Ben George, William Adrian Hall, Beth Erickson, Douglas B. Evans, Susan Tsai. Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase II trial of neoadjuvant therapy and surgery, ASCO Annual Meeting, 2017, June 2-6, 2017 Chicago, IL J Clin Oncol 35, 2017 (suppl; abstr e15766)
74. David Michael Waterhouse, Jonathan Wade Goldman, Ben George, Peter J. O'Dwyer, Moncy Ye, Tianlei Chen, Nataliya Trunova, Karen Kelly. Nivolumab (nivo) + nab-paclitaxel (nab-P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study. ASCO Annual Meeting, 2017, June 2-6, 2017 Chicago, IL. J Clin Oncol 35, 2017(suppl; abstr 9095).
75. Waterhouse, David Michael; Goldman, Jonathan Wade; George, Ben; O'Dwyer, Peter J; Ye, Moncy; Chen, Tianlei; Trunova, Nataliya; Kelly, Karen; Nivolumab (nivo)+ nab-paclitaxel (nab-P)+ carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study: American Society of Clinical Oncology, 2017.
76. Barnes CA, Aldakkak M, Christians KK, Tolat P, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase Ii clinical trial of neoadjuvantherapy and surgery. 51st Annual Pancreas Club. 2017 Chicago, IL
77. Wittmann,D, Aldakkak M, Rajamanickam EP, Christians KK, Aburajab M, George B, Ritch PS, Hall WA, Erickson BA, Evans, DB, Tsai S. Impact of perioerative changes in CA19-9 levels in patients with resectable and borderline resectable pancreatic cancer. Poster of Distinction. 51st Annual Pancreas Club. 2017 Chicago, IL
78. Jeong SY, Aldakkak M , Ahn K, Huang C, Christians KK, EricksonBA, Ritch PS, George B, Evans DB, Tsai S. Preoperative Nomogram to Predict Survival for Patients with Resectable and Borderline Resectable Pancreatic Cancer. 51st Annual Pancreas Club. 2017 Chicago, IL
79. Barnes, Chad; Aldakkak, Mohammed; Christians, Kathleen K; Tolat, Parag; Ritch, Paul S; George B, Hall, William Adrian; Erickson, Beth; Evans, Douglas B; Tsai, Susan;Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase II trial of neoadjuvant therapy and surgery: American Society of Clinical Oncology, 2017.
80. Saeed, H; Cheng, H; Aldakkak, M; Tsai, S; Evans, DB; Christians, K; Thomas, J; George B, Ritch, P; Hall, WA; Neoadjuvant Chemoradiation With IMRT for Pancreatic Cancer is Associated With Minimal Toxicity without Compromising Local Control. International Journal of Radiation Oncology, Biology, Physics. 2017;99: E184-E185.
81. Campbell, Brittany B; Angelini, Paola; Fabrizio, David; Elvin, Julia; Light, Nicholas; Bouffet, Eric; Larouche, Valerie; Samuel, David; Stearns, Duncan; Cole, Kristina. IMMU-13. LARGE SCALE TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE PREDISPOSITION AND REVEALS NOVEL CANDIDATES FOR IMMUNE CHECKPOINT INHIBITION. Neuro-Oncology. 2017;19: iv30-iv30.
82. Angelini, P; Sabel, M; Larouche, V; Opocher, E; Lindhorst, S; Ziegler, D; George B, Oren, M; Tomboc, P; Samuel, D. Encouraging Responses and Survival for Patients with Replication Repair Deficiency and Hypermutant Cancers to Immune Checkpoint Inhibition. A Report from the International bMMRD Consortium. PEDIATRIC BLOOD & CANCER: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2017:S53-S53.
83. Singavi AK, Menon S, Kilari D, Alqwasmi AH, Thomas JP, Ritch PS, Martin A, Oxencis C, Ali SM, George B. Predictive biomarkers for Hyper-progression (HP) in response to Immune Checkpoint Inhibitors (ICI) a?? Analysis of Somatic Alterations(SAs). ESMO 2017 Congress, September 8-12, Madrid, Spain (Merit award for Singavi AK).
84. Narra RK, Singavi AK, Ritch PS, Thomas JP, Alqwasmi AH, George B. Therapeutic relevance of homologous recombination repair (HRR) pathway variants in metastatic colorectal cancer. GI ASCO 2018, January 18-20, San Francisco, CA.
85. Singavi AK, Szabo A, Thomas JP, Ritch PS, Alqwasmi AH, White S, Rilling WS, George B. Costs of Care with Liver Directed Therapy (LDT) and Sorafenib (S) in Patients with Advanced Hepatocellular Carcinoma (HCC). GI ASCO 2018, January 18-20, San Francisco, CA.
86. George B, Greenbowe J, Hendifar AE, Golan T, Javle MM, Maitra A, Bahary N, Yakirevich E, Ritch PS, Thomas JP, Schrock AB, Miller VA, Stephens PJ, Ross JS, Ali SM, Singhi A. Comprehensive Genomic Profiling (CGP) in KRAS Wild-Type (WT) Pancreatic Ductal Adenocarcinoma (PDAC). GI ASCO 2018, January 18-20, San Francisco, CA.
87. Aatur D. Singhi, Joel R. Greenbowe, Jon Chung, Andrew Eugene Hendifar, Nathan Bahary, Alexa Betzig Schrock, Vincent A. Miller, Philip J. Stephens, Jeffrey S. Ross, Siraj Mahamed Ali, Ben George. Comprehensive genomic profiling to identify recurrent kinase fusions in pancreatic ductal adenocarcinoma. GI ASCO 2018, January 18-20, San Francisco, CA
88. Narra KR, Singavi A, Thompson J, Menon S, Oxencis, C, Riese M, Thomas JP, Ritch P, Kilari D, Szabo A, George B. Application of comprehensive genomic profiling (CGP) to predict therapeutic response to immune checkpoint Inhibitors (ICI). AACR 2018, April 14-18, Chicago, IL.
89. Tsai S, Christians K, George B, Paul R, Dua K, Khan A, Mackinnon AC. Tolat P, Hall W, Erickson B, Evans D; A Prospective Clinical Trial of Personalized Medicine for Operable Pancreatic Cancer. American Surgical Association, 138th Annual Meeting, April 19-20, 2018, Phoenix, AZ.
90. Wong M, Kim J, Robbins J, George B, Zimmerman M, Hong J; Outcomes Analysis of Liver Transplantation Combined with Neoadjuvant Therapy in Patients with Unresectable Locally-Advanced Cholangiocarcinoma. Society of Asian Academic Surgeons 3rd Annual Meeting, September 27-28, 2018, Milwaukee, WI.
91. Barnes C, Aldakkak M, Clarke C, Christians K, Aburajab M, George B, Ritch P, Hall W, Erickson B, Evans D, Tsai S; Operative Management of Locally Advanced Pancreatic Cancer: Analysis of the National Cancer Database. Society of Asian Academic Surgeons 3rd Annual Meeting, September 27-28, 2018, Milwaukee, WI.
92. Barnes C, Cho Y, Aldakkak M, Clarke C, Christians K, Khan A, George B, Ritch P, Hall W, Erickson B, Evans D, Tsai S; Conditional Survival for Patients with Localized Pancreatic Cancer Treated with Neoadjuvant Therapy and Surgery a?? A Single Institution Experience. Society of Asian Academic Surgeons 3rd Annual Meeting, September 27-28, 2018, Milwaukee, WI
93. Stein A, George B, Thomas J, Tsai S, Clarke C, Gamblin T, Mogal H; Molecular and Genetic Markers in Appendiceal Mucinous Neoplasms a?? A Systematic Review. Society of Asian Academic Surgeons 3rd Annual Meeting, September 27-28, 2018, Milwaukee, WI.
94. Kelm S, Longo J, Bedi M, Siker, M, Thomas J, George B, Ludwig K, Peterson C, Ridolfi T, Erickson B; The Impact of Hemoglobin on Outcomes in Anal Canal Cancer Treated with Definitive Chemoradiation. ASTRO Annual Meeting, October 21, 2018, San Antonio, TX
95. Johnson M, Patel M, Ulahannan S, Hansen A, George B, Chu Q, Elgadi M, Ge M, Duffy C, Graeser R, Khedkar, Jones S, Burris H; Phase 1 Study of BI 754111 (anti-LAG-3) plus BI 754091 (anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L) 1-pretreated non-small-cell lunch cancer (NSCLC) and other solid tumors. 2018 ESMO Congress, October 19-23 2018, Munich, Germany
96. Johnson, ML; Patel, MR; Ulahannan, SV; Hansen, A; George B; Chu, QS-C; Elgadi, M; Ge, M; Duffy, C; Graeser, R; Phase I study of BI 754111 (anti-LAG-3) plus BI 754091 (anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic colorectal cancer (mCRC), anti-PD-(L) 1-pretreated non-small cell lung cancer (NSCLC) and other solid tumors. Annals of Oncology. 2018;29: viii441.
97. Barnes, Chad; Cho, Youngjoo; Aldakkak, Mohammed; Clarke, Callisia; Christians, Kathleen; Dua, Kulwinder S; Lomberk, Gwen; Urrutia, Raul; George B; Ritch, Paul S.962-Conditional Survival Following Neoadjuvant Therapy and Surgery for Patients with Localized Pancreatic Cancer from the National Cancer Database. Gastroenterology. 2018;6: S-1298.
98. Wainberg ZA, Hochster HS, Kim EJH, George B, Kalyan A, Chiorean GE, Waterhouse DM, Gutierrez M, Parikh AR, Jain R, Carrizosa DR, Hussein S, Bhore R, Banerjee S, Lyons L, Louis CU, Jin Ong P, Oa??Dwyer PJ. Phase I study of nivolumab (nivo) + nab- paclitaxel (nab-P) A? gemcitabine (Gem) in advanced pancreatic cancer. GI ASCO, 2019
99. Van Cutsem E, Hochster H, Kohei S, Mayer R, Ohtsu A, Falcone A, Yoshino T, Doi T, Ilsond, Arkenau T, George B, McGuigan S, Makris L, Tabernero J Pooled Safety Analysis From Phase 3 Studies of Trifluridine/tipiracil (FTD/TPI) in Patients (pts) with Metastatic Gastric/Gastroesophageal Junction Cancer (mGC/mGEJC) and Metastatic Colorectal Cancer (cCRC). ASCO Annual Meeting, 2019 May 31-June 4, Chicago, IL
100. Ilson DH, Prokharau A, Arkenau HT, Ghidini M, Fujitani K, Van Cutsem E, Thuss-Patience PC, Beretta GD, Masoor W, Zhavrid E, Alsina M, George B, Catenacci D, Winkler R, Makris L, Doi R, Shitara K. Efficacy and Safety of Trifluridine/Tipiracil (FTD/TPI) in patients (pts) with metastatic gastric cancer (mGC) with or without prior gastrectomy; Results from a phase III study (TAGS) Oral Presentation. GI ASCO January 17, 2019
101. Sohal D, Doudement J, George B, Alexander B, Grant SC, Kim WY, Gutierrez ME, Kelly KW, Knudsen KE, McPherson JD, Hoimes C, Davis EJ, Singal G, Webster J, Chan L, Cristofanilli M, Miller VA. Accelerating Advanced Precision Medicine Through a Harmonized Data Exchange Platform and Research Consortium (PMEC). ASCO Annual Meeting, 2019 May 31-June 4, Chicago, IL
102. Bendell, Johanna; Ulahannan, Susanna V; Chu, Quincy; Patel, Manish; George B; Landsberg, Renee; Elgadi, Mabrouk; Duffy, Christine; Graeser, Ralph; Tang, Wenbo. Abstract C027: A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort: AACR, 2019.
103. Krepline, AN; Barnes, CA; Aldakkak, M; Akinola, I; Christians, KK; Clarke, CN; George B; Ritch, PS; Hall, W; Erickson, BA; Role of neoadjuvant radiation in downstaging patients with localized pancreatic cancera??analysis of the ncdb database. HPB. 2019;21: S87-S88.
104. Bouffet, Eric; Sudhaman, Sumedha; Chung, Jiil; Campbell, Brittany; Kelly, Jacalyn; Coblentz, Ailish; Edwards, Melissa; Lipman, Tatiana; Zhang, Cindy; Ercan, Ayse Bahar; IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. Neuro-Oncology. 2019;21: ii96-ii97.
105. Peter Thuss-Patience, Sylvie Lorenzen, Thomas Ettrich, Meinolf Karthaus, David H. Ilson, Aliaksandr Prokharau, Tobias Arkenau, Michele Ghidini, Kazumasa Fujitani, Eric Van Cutsem, Giordano D. Beretta, Wasat Mansoor, Edvard Zhavrid, Maria Alsina, Ben George, Daniel Catenacci, Lukas Makris, Toshihiko Doi, and Kohei Shitara. Wirksamkeitund Sicherheit von Trifluridin/Tipiracil (FTD/TPI) bei Patientinnen und Patienten mit metastasiertem Magenkarzinom (mGC) mit oder ohne vorherige Gastrektomie: Ergebnisse einer Phase-III-Studie (TAGS). Encore presentation. Annual DGHO Meeting, Berlin, Germany October 11-15, 2019
106. Hall, William Adrian; Tsai, Susan; Banerjee, Anjishnu; George, Ben; Ritch, Paul S; Thomas, James P; Paulson, Eric; Christians, Kathleen K; Clarke, Callisia; Dua, Kulwinder; A randomized, phase II clinical trial of preoperative stereotactic body radiation therapy versus conventionally fractionated chemoradiation for resectable, borderline-resectable, or locally advanced type a pancreatic adenocarcinoma: American Society of Clinical Oncology, 2019.
107. Bendell J, Ulahannan S, Chu Q, Patel M, George B, Elgadi M, Duffy C, Graeser R, Tang W, Merger M, Ge M, Johnson M. A Phase I, dose finding study of BI 754111, an anit-LAG-3 antibody, in combination with BI 754091, and anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable metastatic colorectal cancer cohort. AACR-NCI-EORTC October 26-30, 2019
108. Bliss L, Krepline A, Barnes C, George B. Does practice make perfect for pancreatic adenocarcinoma? Higher volume centers delivering chemoradiation are associated with improved surgical and survival outcomes. HPB. 2019;21: S143.
109. Kollu, Vidya; Singhavi, Arun; Ritch, Paul S; Thomas, James P; Szabo, Aniko; George, Ben; Not all tumors are created equal: Evaluating the impact of comprehensive genomic profiling (CGP) on clinical outcomes in esophageal/gastroesophageal cancer (GEJ CA): AACR, 2019.
110. Lau J, Teichgraeber V, Lopez C, Allen S, Barak H, Kim Kyu-pyo, Chung V, Ci B, George B, Oh Do-Youn, Kindler H, Zhang X, Shemesh C, Alistar A, Retiere A-C. Phase Ib/II, open-label, randomized evaluation of atezolizumab plus RO6874281 vs control in MORPHEUSa??pancreatic ductal adenocarcinoma (PDAC). ESMO GI, Spain September 18-22, 2020
111. George B; Cockrum, P; Lamarre, N; Surinach, A; PCN17 Real-World Impact of Prior surgery on Outcomes of Patients with Metastatic Ductal Adenocarcinoma (mPDAC) Treated with Liposomal Irinotecan-Based Regimens. Value in Health. 2021;24: S21
112. Krepline, A; Clarke, CN; Christians, K; Ritch, P; George B; Khan, A; Kulkarni, N; Hagen, C; Erickson, B; Hall, W; Multimodality Neoadjuvant Therapy Increases Normalization of Carbohydrate Antigen 19-9 (CA19-9) in Patients with Pancreatic Cancer. ANNALS OF SURGICAL ONCOLOGY: SPRINGER 233 SPRING ST, NEW YORK, NY 10013 USA, 2019:S151-S152.
113. Juloori, A; Liao, CY; Lemons, JM; Singh, AK; Iyer, R; Robbins, JR; George B; Fung, J; Pillai, A; Arif, F; Phase I Study of Stereotactic Body Radiotherapy followed by Ipilimumab with Nivolumab vs. Nivolumab alone in Unresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology, Biology, Physics. 2020;108: S149-S150.
114. Shreenivas A, Guru Murthy GU, George B, Thomas JP, Chakrabarti S, Kamgar M, Ritch P, Medical College of Wisconsin, Froedtert & The Medical College of Wisconsin, Milwaukee, WI; Mayo Clinic, Rochester, MN.Impact of tumor histology and socioeconomic factors on survival of patients suffering from malignant vascular tumors of liver and hepatocellular carcinomas: A SEER database analysis. ASCO Annual Meeting. May 29-June 2, 2020
115. George B, Taylor B, Lasowski M, Ritch P, Shreenivas A, Chakrabarti S, Kamgar M, Zimmermann M, Reddi H, Urrutia R, Thomas JP, A phase I, first-in-human, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP 1287 administered daily to patients with advanced solid tumors.Prognostic effect of specific RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC). ASCO Annual Meeting, Chicago, IL May 29-June 2, 2020
116. Chung, J; Maruvka, Y; Sudhaman, S; Kelly, J; Haradhvala, N; Bianchi, VJ; Edwards, M; Forster, V; Nunes, N; Galati, M; DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Nomral and Malignant Human Cells. PEDIATRIC BLOOD & CANCER: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, 2020:S4-S5.
117. Strong, Erin; Livingston, Austin; Tsai, Susan; Christians, Kathleen; George B; Ritch, Paul; Thomas, James; Dua, Kulwinder; Khan, Abdul; Hunt, Brian; Factors Associated With Dying from Pancreatic Neuroendocrine Tumor. PANCREAS: LIPPINCOTT WILLIAMS & WILKINS TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA a?|, 2020:488-489.
118. Annunzio, K, Griffiths, C, Arapi, I, Lasowsksi, M, Singavi, A, Dua, K, Khan A, Ritch P, Kamgar M, Thomas JP, Hall, W, Erickson B, Tsai S, Christians KK, Evans DB, Raul Urrutia, Szabo, A, George, B. CDKN2A/B status has predictive impact in Pancreatic Cancer (PC). GI ASCO, San Francisco, CA January 23-25, 2020
119. Chiorean EG, Ritch P, Zhen D B, Poplin E, George B, Hendifar A E, Dragovich T, Coveler A L, Stoll-D'Astice A, Edwards S, Rosenthal A, Thorsen SM, Hingorani SR. PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA). GI ASCO, San Francisco, CA January 23-25, 2020
120. Menon S, Ellis C, Poudel S, Johnson J, Szabo A, George B, Kelly K, Grant S, McPherson J, Davis E, Cristofanilli M, Hoimes C, Gutierrez M, Doudement J, Chan L, Singal G, Alexander B, Miller V, Sohal D. Impact of STK11 and c-MYC alterations in metastatic NSCLC. AACR/IASLC Meeting San Diego, CA, Jan 11-14, 2020
121. George B, Van Cutsem E, Hochster H, Mayer R, Ohtsu A, Falcone A, Yoshino T, Doi T, Ilson D, Arkenau H-T, Benhadji K A, Makris L, Tabernero J, Shitara K Analysis of hematologic adverse events in trifluridine/tipiracil (FTD/TPI)-treated patients with or without renal/hepatic impairment: Pooled safety analyses from TAGS and RECOURSE. GI ASCO, San Francisco, CA January 23-25, 2020
122. Bendell J, Ulahannan SV, Chu Q, Patel M, George B, Auguste A, Leo-Kress T, Bernd Stadermann K, Kraemer N, Elgadi M, Johnson M. A Phase I study of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb: biomarker analyses from the microsatellite stable metastatic colorectal cancer (MSS mCRC) cohort. AACR 2020, San Diego, CA April 20-24, 2020
123. Kim, R; Christians, K; Aldakkak, M; Clarke, C; George B; Ritch, P; Kamgar, M; Kulkarni, N; Khan, A; Hall, W; Total Neoadjuvant Therapy For Resectable And Borderline Resectable Pancreatic Cancer. HPB. 2020;22: S54.
124. Lasowski, M, Stachowiak, S, Arapi, I, Dua, K, Khan, A, Hall, W, Erickson, B, Tsai, S, Christians, KK, Evans, DB, Ritch, P, Kamgar, M, Thomas, JP, Raul Urrutia, George B. Utilization of Somatic Comprehensive Genomic Profiling (CGP) to identify patients (pts) with Pancreatic Cancer (PC) that harbor germ line DNA Damage Repair (DDR) gene alterations GI ASCO, San Francisco, CA January 23-25, 2020
125. George B, Richards D, Edenfield WJ, Warner S, Mouritsen L, Bishop R, Anthony S, Bearss S, Vogelzang N, Whatcott C, FH/MCW, US Oncology Research, Tyler, TX: Institute for Translational Oncology Research, Prisma Health-Upstate Cancer Institute, Greenville, SC; Tolero Pharmaceuticals, Inc., Lehi, UT; Tolero Pharmaceuticals, Inc, Lehi, UT; Comprehensive Cancer Centers of Nevada, Las Vegas, NV A phase I, first-in-human, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP 1287 administered daily to patients with advanced solid tumors.ASCO Annual Meeting, Chicago, IL May 29-June 2, 2020
126. Chung V, Alistar A, George B,Kim K-P, Kindler H, Oh D-Y, Allen S, Barak H, Ci B, Lau J, Retiere A-C, Shemesh C, Teichgr??ber V, Zhang X, Lopez C. Phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUSa??pancreatic ductal adenocarcinoma (PDAC). ESMO GI Congress, July 1-4, 2020
127. Johnson M, Patel M, Cherry M, Kang Y-K, Yamaguchi K, Oh D-Y, Hussein M, Kitano S, Kondo S, Hansen AR, Percent IJ, George B, Arrowsmith E, Morimoto M, Duffy C, Ge M, Rohrbacher M, Elgadi M, Bendell J. Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors ASCO Annual Meeting. May 29-June 2, 2020
128. Menon, S; Ellis, C; Poudel, S; Johnson, J; Szabo, A; George B; Kelly, W Kevin; Grant, S; McPherson, J; Cristofanilli, M; B08 Impact of Concurrent STK11 Loss and c-MYC Amplification in Metastatic Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 2020;15: S29-S30.
129. George B; Richards, Donald A; Edenfield, William Jeffery; Warner, Steven L; Mouritsen, Lars; Bishop, Reyna; Anthony, Stephen Patrick; Bearss, David; Vogelzang, Nicholas J; Whatcott, Clifford; A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors: American Society of Clinical Oncology, 2020.
130. Bouffet E, Sudhaman S, Chung J, George B, IMMU-18. favorable outcome in replication repair deficient hypermutant brain tumors to immune checkpoint inhibition: An international rrd consortium registry study. Neuro-Oncology. 2020;22: iii363-iii363.
131. George B; Van Cutsem, Eric; Hochster, Howard S; Mayer, Robert J; Ohtsu, Atsushi; Falcone, Alfredo; Yoshino, Takayuki; Doi, Toshihiko; Ilson, David H; Arkenau, Hendrik-Tobias; Analysis of hematologic adverse events (HeAEs) in trifluridine/tipiracil (FTD/TPI)-treated patients (pts) with or without renal/hepatic impairment (RI/HI): Pooled safety analyses from TAGS and RECOURSE: American Society of Clinical Oncology, 2020.
132. Chung, Vincent; Alistar, Angela; George B; Kim, K; Kindler, Hedy; Oh, D; Allen, Simon; Barak, Hila; Ci, Bo; Lau, Janet; SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUSa??pancreatic ductal adenocarcinoma. Annals of Oncology. 2020;31: S218.
133. Laursen, Ashley Ann; Surinach, Andy; Wang, Shu; Cockrum, Paul; George B; Real-world patterns of pain medication use among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): American Society of Clinical Oncology, 2021.
134. Ahmed, Gulrayz; Annunzio, Kaitlin; Szabo, Aniko; Eastwood, Daniel; Thapa, Bicky; Taylor, Bradley W; Tsai, Susan; Christians, Kathleen K; Clarke, Callisia; Evans, Douglas B;Clinical outcomes in pancreatic ductal adenocarcinoma (PDAC) patients with underlying autoimmune disease (AID): Wolters Kluwer Health, 2021.
135. Mehdi, Maahum; Kamgar, Mandana; George B; Szabo, Aniko; Annunzio, Kaitlin; Taylor, Bradley W; Shreenivas, Aditya Varnam; Chakrabarti, Sakti; Thomas, James P; Tsai, Susan; Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC): Wolters Kluwer Health, 2021.
136. Sabari, Joshua K; Park, Haeseong; Tolcher, Anthony W; Ou, Sai-Hong Ignatius; Garon, Edward B; George B; Janne, Pasi A; Moody, Susan Elizabeth; Tan, Eugene Y; Sen, Suman Kumar; KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation: American Society of Clinical Oncology, 2021.
137. George, Ben; Chudnovsky, Aleksander; Cockrum, Paul; Lamarre, Neil; Kent, Matthew; Surinach, Andy; The association between real-world CA19-9 level monitoring patterns and with clinical outcomes among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the second-and third-line of therapy: Wolters Kluwer Health, 2021.
138. Jurkowski, Lauren; Shreenivas, Aditya Varnam; Chakrabarti, Sakti; Kamgar, Mandana; Thomas, James P; Puckett, Lindsay; Shukla, Monica; Gore, Elizabeth; Evans, John; Johnstone, Candice Aitken; Association of total neoadjuvant therapy with favorable clinical outcomes in patients with locally advanced esophageal and gastroesophageal junction adenocarcinomas (LA-GEJ CA): American Society of Clinical Oncology, 2021.
139. George, Ben; Haberberger, James; Ferguson, Naomi L; Gjoerup, Ole; McGregor, Kimberly; Hendifar, Andrew Eugene; Laheru, Daniel A; Weekes, Colin D; Ross, Jeffrey S; Hemmerich, Amanda; Comprehensive genomic profiling (CGP) utilizing cell-free DNA (cfDNA) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC): American Society of Clinical Oncology, 2021.
140. Ortiz, S; Visotcky, A; Banerjee, A; Aldakkak, M; Tsai, S; Evans, DB; Christians, K; Clarke, CN; George, B; Shreenivas, A; Examination for the Presence of an Oligo-Metastatic State in Patients with Newly Diagnosed Metastatic Pancreatic Adenocarcinoma Undergoing Systemic Chemotherapy. International Journal of Radiation Oncology, Biology, Physics. 2021;111: e66-e67.
141. Shitara, Kohei; George, Ben; Taieb, Julien; Sundar, Raghav; Fakih, Marwan G; Makris, Lukas; Benhadji, Karim A; Ghidini, Michele; The impact of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in the phase III TAGS trial. Presented at the Virtual ASCO Gastrointestinal Cancers Symposium, 2021.
142. George B, Haberberger J, Ferguson NL, Correlation between comprehensive genomic profiling (CGP) utilizing tissue-based testing (T-CGP) and cell-free DNA (cfDNA) in patients (pts) with pancreatic ductal adenocarcinoma (PDAC): American Society of Clinical Oncology, 2021
143. Hall, William A; Khan, Husain Y; Kamgar, Mandana; Tsai, Susan; Christians, Kathleen; Evans, Douglas B; Philip, Philip; Clarke, Callisia; George, Ben; Erickson, Beth;Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiotherapy: AACR, 2021.
144. Shreenivas, Aditya Varnam; Annunzio, Kaitlin; Kamgar, Mandana; Chakrabarti, Sakti; Thomas, James P; Madhavan, Srivats; Dua, Kulwinder; Khan, Abdul H; Hall, William Adrian; Erickson, Beth; Impact of KRAS alterations in localized pancreatic cancer (PC): American Society of Clinical Oncology, 2021.
145. Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors. 2020 American Society of Clinical Oncology
146. Thalji, SZ; Aldakkak, M; Christians, KK; Clarke, CN; George B; Kamgar, M; Erickson, BA; Hall, WA; Khan, A; Tolat, P; Goal-directed neoadjuvant treatment of operable pancreatic cancer: achieving CA19-9 response to chemotherapy prior to surgery. HPB. 2021;23: S478-S479.
147. Thalji, Sam; Hall, William; Aldakkak, Mohammed; Christians, Kathleen; Clarke, Callisia N; George, Ben; Kamgar, Mandana; Hunt, Bryan; Madhavan, Srivats; Kulkarni, Naveen; 899 MAGNITUDE OF CA19-9 DECLINE IN RESPONSE TO NEOADJUVANT CHEMORADIATION IS ASSOCIATED WITH OVERALL SURVIVAL IN PATIENTS WITH PANCREATIC CANCER. Gastroenterology. 2021;160: S-902.
148. Thalji S, Kamgar M, George B. CA19-9 Response to 1st-Line Neoadjuvant FOLFIRINOX and 2nd-Line Gemcitabine-Based Chemotherapy in Patients with Operable Pancreatic Cancer. ANNALS OF SURGICAL ONCOLOGY: SPRINGER ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES, 2021:S20-S20.
149. Thapa, Bicky; Ahmed, Gulrayz; Lasowski, Matthew; Thomas, James P; Reddi, Honey V; Zimmerman, Michael T; Urrutia, Raul; Szabo, Aniko; George, Ben; Comprehensive genomic profiling-does timing matter: AACR, 2021.
150. Ward, EP; Christians, KK; Kamgar, M; George B; Griffin, M; Hunt, B; Chisholm, P; Hall, WA; Erickson, B; Evans, DB; Elevated postoperative CA19-9 in patients with pancreatic cancer following the completion of neoadjuvant therapy and surgery-implications for adjuvant therapy and surveillance. HPB. 2021;23: S510.
151. Yoshino, O; Aldakkak, M; Seadler, B; Tsai, S; Kim, RY; Kamgar, M; Hall, WA; Clarke, CN; George, B; Erickson, B; Arterial divestment (AD) versus arterial resection/reconstruction (AR) at the time of pancreatectomy for locally advanced pancreas cancer (LAPC). HPB. 2021;23: S461.
152. George, Ben; Kent, Matthew; Surinach, Andy; Lamarre, Neil; Cockrum, Paul; Chudnovsky, Aleksander; Real-world serum CA19-9 level monitoring patterns and its association with clinical outcomes among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): AACR, 2021.
153. Kim, R; Tsai, S; Aldakkak, M; George, B; Kamgar, M; Erickson, B; Kulkarni, N; Evans, D; Christians, K; Factors Associated with Overall Survival in Pancreatic Cancer Treated with Neoadjuvant Therapy and Surgery. HPB. 2021 23;S60
154. Zhen, David Bing; Whittle, Martin; Ritch, Paul S; Hochster, Howard S; Coveler, Andrew L; George B; Hendifar, Andrew Eugene; Dragovich, Tomislav; Green, Steven; Dion, Barbara; Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic adenocarcinoma (mPC): PCRT16-001: GI ASCO, 2022.
155. Shreenivas, Aditya V; George B; Thomas, James P; Puckett, Lindsay; Chakrabarti, Sakti; Awan, Musaddiq; Straza, Michael Wayne; Hall, William A; Loy, Veronica; Rilling, William S. Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic. GI ASCO 2022
156. Abid, Haisam; Szabo, Aniko; Taylor, Bradley W; Shreenivas, Aditya V; Chakrabarti, Sakti; Kamgar, Mandana; Thomas, James P; George B. Prognostic effect of RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC):GI ASCO, 2022
157. Mehdi, Maahum; Annunzio, Kaitlin; Taylor, Bradley W; Szabo, Aniko; Shreenivas, Aditya V; Chakrabarti, Sakti; Thomas, James P; Tsai, Susan; Christians, Kathleen K; Evans, Douglas B; Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response: GI ASCO, 2022.
158. McKenna, Edward; Oxencis, Carolyn; Parish, Marie; Eastwood, Daniel; Miller, James; Shreenivas, Aditya V; Kamgar, Mandana; George B; Hall, William A; Erickson, Beth; Survival outcome and treatment response of patients with young-onset locally advanced rectal cancer (YO-LARC) receiving total neoadjuvant therapy (TNT):GI ASCO, 2022.
159. Parish, Marie; Cox, Ronald; Thapa, Bicky; McKenna, Edward; Oxencis, Carolyn; Shreenivas, Aditya V; Kamgar, Mandana; George B; Thomas, James P; Chakrabarti, Sakti; Clinical course and outcome of patients developing capecitabine-induced non-neutropenic enterocolitis (NNEC): An institutional analysis: GI ASCO, 2022.
160. George B; Thalji, Samih; Malarkannan, Subramaniam; Kudryashova, Olga; Kravets, Andrey; Gusakova, Mariia; Kravchenko, Dmitry; Tychinin, Dmitry; Frenkel, Felix; Bagaev, Aleksander; Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer: GI ASCO, 2022.
161. Shreenivas AV, George B, Thomas JP. concocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study: GI ASCO, 2022.
162. Puckett, Lindsay; Matoska, George B, Thomas; Jurkowski, Lauren; Banerjee, Anjishnu; Martinez, Enrique; Kodali, Divya; Shukla, Monica; Linsky, Paul; Gasparri, Mario; Chakrabarti, Sakti; Definitive chemoradiation for oligometastatic esophageal cancer patients: GI ASCO, 2022.